Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026
GlobeNewswire, Inc.
SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for...
Sweden Reassures Public Over Hantavirus Outbreak Linked to Cruise Ship
MENAFN
(MENAFN) Swedish health officials have moved to calm public concern over a hantavirus outbreak connected to the cruise ship MV Hondius, saying there is no indication of a wider public health threat or emerging pandemic, according to reports from...
Acoustic Camera Market Report Highlights 3.53% CAGR and USD 235.50 Billion Opportunity by 2035
EIN Presswire
Acoustic Camera Market Size, Share and Research Report By Component (Hardware, Software), By Application (Industrial Inspection, Automotive Testing) PARIS, PARIS, FRANCE, August 20, 2026 /EINPresswire.com/ -- The Global acoustic camera market...
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
GlobeNewswire, Inc.
Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor...
Rally in Stockholm Condemns Israeli Military Actions in Gaza, Lebanon
MENAFN
(MENAFN) Hundreds of demonstrators gathered in central Stockholm on Saturday to protest Israel’s military operations in the Palestinian territories and Lebanon.
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
GlobeNewswire, Inc.
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14/20) CR/CRh in...
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
GlobeNewswire, Inc.
Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional...
Half-Year Results 2026: Boskalis delivers solid performance amid challenging market conditions
GlobeNewswire, Inc.
Papendrecht, 20 August 2026 KEY FIGURES FIRST HALF YEAR 2026 Revenue: EUR 1.90 billion (H1 2025: EUR 2.35 billion) EBITDA: EUR 553 million (H1 2025: EUR 748 million) Net profit: EUR 275 million (H1 2025: EUR 426 million) Order book: EUR 6.8...
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
GlobeNewswire, Inc.
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m...
Chiesi Global Rare Diseases Announces Health Canada Grants Priority Review for FILSUVEZ® (birch triterpenes) Topical Gel for the Treatment of Epidermolysis Bullosa
GlobeNewswire, Inc.
Priority review recognizes the serious nature of epidermolysis bullosa (EB) and the urgent need for continued evaluation of potential treatment options If approved, FILSUVEZ has the potential to become the first therapy approved by Health Canada...
Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)
GlobeNewswire, Inc.
PARMA, Italy, June 05, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that the European...
Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz
GlobeNewswire, Inc.
CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its proprietary brand, Sky Premium Life, is now...
Chiesi Global Rare Diseases to Launch the Second Edition of Find For Rare at 2026 ERA Congress to Advance Research in Lysosomal Storage Disorders
GlobeNewswire, Inc.
-- At ERA 2026, Chiesi will contribute to advancing the scientific understanding of Fabry disease and nephropathic cystinosis through real-world experience and clinical outcomes, supporting the needs of the community of today -- -- Chiesi will...
FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
GlobeNewswire, Inc.
Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward...
Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
GlobeNewswire, Inc.
BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver...
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
GlobeNewswire, Inc.
SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat...
Imviva Biotech to Present Data from Clinical Studies of CTA313 and CTD402 Validating its ANSWER™ Allogeneic CAR-T Platform in Pediatric and Adult Patient Populations at EULAR and EHA 2026 Congresses
GlobeNewswire, Inc.
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present data on CTA313, its investigational dual-targeted...
5,000 Swedes sign on to protect the Swedish success story
GlobeNewswire, Inc.
STOCKHOLM, May 21, 2026 (GLOBE NEWSWIRE) -- The campaign Den Svenska Succén has today passed 5,000 signatures from Swedes calling for snus and white snus to be protected as a cornerstone of Sweden's public health policy.
CryoTEM breaks ground as new method added to U.S. Pharmacopeia's updated AAV reference standard certificates
EIN Presswire
USP recognizes CryoTEM for characterizing empty/full/intermediate capsids on AAV8 reference standards STOCKHOLM, STOCKHOLM, SWEDEN, May 20, 2026 /EINPresswire.com/ -- QuTEM announces that cryo-transmission electron microscopy (CryoTEM) has been...
Philips to deliver vital technology for hospital-at-home care for up to 15,000 patients annually in Region Stockholm
GlobeNewswire, Inc.
May 18, 2026 Philips-led consortium selected through Karolinska University Hospital-led Region Stockholm tender to deliver advanced remote monitoring for complex patients Stockholm, Sweden - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in...
Sign up for:
Swedish Health Press
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.